Marinus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
02 juin 2020 16h01 HE
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 18,400,000...
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
28 mai 2020 21h23 HE
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., May 28, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock
28 mai 2020 16h01 HE
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., May 28, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
04 mai 2020 07h30 HE
|
Marinus Pharmaceuticals, Inc.
Constructive End of Phase 2 Meeting with FDA for Status Epilepticus Completed in March; Pivotal Phase 3 Clinical Trial Expected to Begin Next Quarter Topline Data on Track for Q3 2020 from Pivotal...
Marinus Pharmaceuticals Announces Formation of Scientific Advisory Board
30 avr. 2020 07h30 HE
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure...
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27 avr. 2020 16h01 HE
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., April 27, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company” or “Marinus”), a pharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 4, 2020
23 avr. 2020 07h30 HE
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure...
MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
23 mars 2020 16h37 HE
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., March 23, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company”, “Marinus”), a pharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications
19 mars 2020 07h30 HE
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., March 19, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure...
Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results
16 mars 2020 07h30 HE
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., March 16, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure...